Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™House Joint Resolution 145 (HJRES 145) from the 118th Congress is a legislative measure aimed at disapproving a specific rule submitted by the Food and Drug Administration (FDA) concerning "Medical Devices; Laboratory Developed Tests." The resolution seeks to use the authority under chapter 8 of title 5, United States Code, to nullify the FDA's rulemaking on this subject. The bill was referred to the House Subcommittee on Health but ultimately failed or expired without further action. No official summary or full text of the bill is publicly available, limiting detailed analysis.
HJRES 145 is a congressional disapproval resolution targeting an FDA rule on laboratory developed tests for medical devices, which did not advance beyond subcommittee referral and expired.
- The bill seeks to disapprove an FDA rule related to medical devices and laboratory developed tests under the Congressional Review Act framework.
- It was introduced in the House and referred to the Subcommittee on Health but did not progress further.
- The bill is categorized under the health policy area and is currently marked as failed or expired.
['Congressional members seeking to overturn the FDA rule', 'Stakeholders in the medical device and laboratory developed test industries who may oppose the FDA rule', 'Potentially patients and healthcare providers depending on the regulatory outcome']
["Lack of publicly available full bill text and official summary limits transparency and detailed understanding of the bill's provisions.", 'The disapproval of an FDA rule may affect regulatory oversight and enforcement related to laboratory developed tests, with implications for public health and safety.', 'The bill’s failure to advance suggests challenges in legislative support or prioritization.']
HJRES 145 operates under the Congressional Review Act, which allows Congress to disapprove federal agency rules. The bill reflects legislative oversight of FDA regulatory actions concerning medical devices and laboratory developed tests. Its referral to the Subcommittee on Health indicates initial committee consideration, but its failure to progress suggests limited legislative momentum during the 118th Congress.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the disapproval could delay or prevent FDA implementation of updated regulatory standards for laboratory developed tests, potentially affecting innovation and patient access.', 'The legislative action may influence future FDA rulemaking approaches or agency-industry interactions in the medical device sector.']
The absence of an official summary and full bill text restricts comprehensive analysis and public understanding of HJRES 145. Monitoring the use of the Congressional Review Act in this context is important for transparency about congressional oversight of FDA regulations. The bill’s failure to advance highlights the challenges in overturning agency rules through this mechanism.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.